Outcome Measures: |
Primary: Effect of Exenatide on postprandial glucose, To compare the effect of exenatide to that of sitagliptin on 2-hour postprandial glucose in subjects with type 2 diabetes mellitus, 28 days | Secondary: Assessment of effect of exenatide to the effect of sitagliptin the acetaminophen absorption test, and 6-point self-monitored blood glucose (SMBG) profiles, To compare the effect of exenatide to the effect of sitagliptin on the following endpoints in subjects with type 2 diabetes mellitus: postprandial glucose, insulin, insulin secretion rate, glucagon, and triglycerides; gastric emptying, as assessed by the acetaminophen absorption test, and 6-point self-monitored blood glucose (SMBG) profiles, 28 days
|
Locations: |
Research Site, Los Angeles, California, United States|Research Site, Spring Valley, California, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, 46260, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Butte, Montana, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinatti, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Eugene, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, San Antonio, Texas, United States
|